Peptide Comparison
AHK-Cu vs Syn-Ake
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
AHK-Cu and Syn-Ake share the cosmetic class and carry roughly equivalent evidence (Cosmetic Clinical Studies / Cosmetic Clinical Studies). The catalogued data does not favor one over the other; pick based on practical fit: route, dosing schedule, cost, regulatory framing, or which specific receptor sub-target matters most for the intended research use.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| AHK-Cu | Syn-Ake | |
|---|---|---|
| Class | Copper tripeptide (cosmetic) | Cosmetic peptide (snake-venom inspired) |
| Drug class | Dermatologic | Dermatologic |
| Mechanism | Copper delivery to hair follicles; angiogenesis and VEGF induction in scalp | Waglerin-1 mimic; antagonizes nicotinic ACh receptor at muscle |
| Route | Topical | Topical |
| Half-life | Topical (no systemic) | Topical |
| Dosage (research) | Topical 0.01-0.1% | Topical 4% |
| Evidence tier | Cosmetic Clinical Studies | Cosmetic Clinical Studies |
| Research depth | 3 indexed | 5 indexed |
| Availability | Cosmetic | Cosmetic |
| Reported risks | Skin irritation; theoretical copper issues | Minimal |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick AHK-Cu or Syn-Ake?
AHK-Cu and Syn-Ake share the cosmetic class and carry roughly equivalent evidence (Cosmetic Clinical Studies / Cosmetic Clinical Studies). The catalogued data does not favor one over the other; pick based on practical fit: route, dosing schedule, cost, regulatory framing, or which specific receptor sub-target matters most for the intended research use.
What is the difference between AHK-Cu and Syn-Ake?
AHK-Cu is classed as Copper tripeptide (cosmetic); Syn-Ake is classed as Cosmetic peptide (snake-venom inspired). Reported mechanism: AHK-Cu, Copper delivery to hair follicles; angiogenesis and VEGF induction in scalp; Syn-Ake, Waglerin-1 mimic; antagonizes nicotinic ACh receptor at muscle. Reported half-life: AHK-Cu, Topical (no systemic); Syn-Ake, Topical. Routes in published studies: AHK-Cu, Topical; Syn-Ake, Topical.
Which has stronger evidence, AHK-Cu or Syn-Ake?
AHK-Cu and Syn-Ake sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. AHK-Cu is graded Cosmetic Clinical Studies, with 3 cited sources on its reference page and 3 indexed studies. Syn-Ake is graded Cosmetic Clinical Studies, with 3 cited sources on its reference page and 5 indexed studies.
Which is more accessible, AHK-Cu or Syn-Ake?
Neither AHK-Cu nor Syn-Ake is an FDA-approved drug. Catalog status: AHK-Cu, Cosmetic; Syn-Ake, Cosmetic.
Are AHK-Cu and Syn-Ake ever combined?
AHK-Cu and Syn-Ake appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…